MedTrace Logo

Intranasal Oxytocin in Antiosocial Personality Disorder and Psychopathy

NCT05383300 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-05-20

No results posted yet for this study

Summary

A pharmacoimaging study of oxytcoin in antisocial personality disorder and psychopathy

Conditions

  • Antisocial Personality Disorder

Interventions

DRUG

Oxytocin nasal spray

Intranasal spray containing 40 IU of oxytocin

OTHER

Placebo spray

Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin

Sponsors & Collaborators

Principal Investigators

  • Nigel Blackwood, MB MD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2020-03-01
Completion
2021-12-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05383300 on ClinicalTrials.gov